Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ATP4A | P20648 | 4/20 | 0.43 |
| ▸ | ATP4B | P51164 | 4/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.42 |
| ▸ | VCP | P55072 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605029 | 0.90 | ATP4A (0.45) | MAPTMEN1KMT2APLAUATP4A | |
| SCHEMBL2380032 | 0.79 | ATP4A (0.50) | MAPTPLAUATP4AATP4BVCP | |
| SCHEMBL3600274 | 0.79 | VCP (0.64) | MAPTMEN1KMT2AATP4AATP4B | |
| SCHEMBL3597985 | 0.77 | ATP4A (0.61) | PLAUATP4AATP4BGSTO1 | |
| SCHEMBL3607242 | 0.76 | AMY1A (0.64) | MAPTMEN1KMT2APKMRORC | |
| SCHEMBL3608371 | 0.76 | GSTO1 (0.64) | MEN1KMT2AATP4AATP4BKDM1A | |
| SCHEMBL30660073 | 0.76 | GSTO1 (0.64) | MEN1KMT2AATP4AATP4BKDM1A | |
| SCHEMBL3598222 | 0.75 | PKM (0.65) | MAPTPKMATP4AATP4BVCP | |
| SCHEMBL3601551 | 0.71 | MAPT (0.51) | MAPTMEN1KMT2APLAUATP4A | |
| SCHEMBL3612827 | 0.71 | ATP4A (0.47) | MAPTMEN1KMT2APLAUATP4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| CN-101466692-A | Thiazol-guanidine derivatives useful as a (beta) - related pathologies | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | claimed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| CN-101466692-A | Thiazol-guanidine derivatives useful as a (beta) - related pathologies | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | disclosed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | MAPT 2/4885MEN1 3257/4885KMT2A 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.